Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 8/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.66 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.66 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.64 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.64 |
| ▸ | NOS1 | P29475 | 1/20 | 0.61 |
| ▸ | NOS2 | P35228 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 3/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11464993 | 0.91 | BCHE (0.68) | BCHECHRM2CHRM1CHRM3CYP4F2 | |
| SCHEMBL25825085 | 0.84 | HTR1B (0.66) | BCHECYP4F2CYP4A11MAOB | |
| SCHEMBL17210775 | 0.84 | CYP4F2 (0.69) | BCHECYP4F2CYP4A11CYP2D6MAOB | |
| SCHEMBL2157904 | 0.83 | BCHE (0.69) | BCHEATMTAAR1 | |
| SCHEMBL2911574 | 0.83 | CHRM2 (0.70) | CHRM2CHRM1CHRM3NOS1NOS2 | |
| SCHEMBL13814621 | 0.83 | BCHE (0.73) | BCHECYP4F2CYP4A11NOS1MAOB | |
| SCHEMBL29683508 | 0.83 | BCHE (0.64) | BCHECYP4F2CYP4A11CYP2D6MAOB | |
| SCHEMBL14032176 | 0.83 | BCHE (0.64) | BCHECYP4F2CYP4A11CYP2D6MAOB | |
| Hydrochloric Acid SCHEMBL29873726 | 0.82 | BCHE (0.71) | BCHECYP4F2CYP4A11NOS1MAOB | |
| Hydrochloric Acid SCHEMBL9454945 | 0.82 | BCHE (0.71) | BCHECYP4F2CYP4A11NOS1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963280-B1 | 2-PHENYLETHYLAMINO DERIVATIVES AS CALCIUM AND/OR SODIUM CHANNEL MODULATORS | NEWRON PHARM SPA (IT) | 2015-10-28 | — | — | EP | disclosed |
| WO-2011006000-A1 | BERBERINE DERIVATIVES USEFUL FOR MODULATING LIPID LEVELS AND THEIR METHODS OF SYNTHESIS | LIU HAIYAN (US) | 2011-01-13 | — | — | WO | disclosed |
| US-7205302-B2 | Anticoagulants; antilipemic agents; cardiovascular disorders | NIPPON SHINYAKU CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| CN-1301973-C | Heterocyclic derivatives and medicines | NIPPON SHINYAKU CO LTD (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1400518-B1 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | NIPPON SHINYAKU CO LTD (JP) | 2007-01-17 | — | — | EP | disclosed |
| CN-1516690-A | Heterocyclic derivatives and medicines | �ձ���ҩ��ʽ���� | 2004-07-28 | — | — | CN | disclosed |
| US-20040102436-A1 | Heterocyclic compound derivatives and medicines | NIPPON SHINYAKU CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1400518-A1 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | Nippon Shinyaku Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-5234946-A | Anticholesterol, antilipemic | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-10 | — | — | US | disclosed |
| EP-0318860-B1 | SUBSTITUTED ALKYLAMINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-06-16 | — | — | EP | disclosed |
| EP-0318860-A2 | Substituted alkylamine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102436-A1 | Heterocyclic compound derivatives and medicines | CNR2, CNR1, GPR55 | BCHE 2630/4885CHRM2 372/4885CHRM1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.